A goat pox virus monoclonal antibody and its application

By recombining goat poxvirus P32 protein truncated protein rGP32Δ and secreted antibody hybridoma cell lines, blocking ELISA detection methods were established, solving the biosafety hazards and detection efficiency of antibody detection in the prior art, and achieving efficient and safe goats Poxvirus antibody detection.

CN115286699BActive Publication Date: 2024-11-29CHINA INST OF VETERINARY DRUG CONTROL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202210428926.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-22
Publication Date
2024-11-29
Estimated Expiration
2042-04-22

AI Technical Summary

Technical Problem

The lack of effective goat pox virus antibody detection kits in the prior art has led to difficulty in screening of antibody-negative animals during the development of goat pox vaccines, and there are biosafety risks in live virus neutralization tests, and there is a lack of fast, sensitive and specific detection methods.

Method used

By obtaining the recombinant goat poxvirus P32 protein truncated protein rGP32Δ and preparing hybridoma cell lines that secrete antibodies, a blocking ELISA detection method is established, and the traditional live virus neutralization test is used to reduce biosafety risks and improve detection efficiency.

Benefits of technology

The expression of high-purity and soluble recombinant proteins is achieved, which reduces biosafety risks, provides fast, sensitive and specific goat poxvirus antibody detection methods, supports vaccine development and efficacy testing, simplifies operations and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115286699B_ABST
    Figure CN115286699B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of medical technology, and specifically to a goat pox virus monoclonal antibody and its application. An immunogenic protein rGP32Δ, the coding sequence of the protein rGP32Δ is shown in the 4th to 717th positions of SEQ ID No.1; the amino acid sequence of the protein rGP32Δ is shown in the 2nd to 239th positions of SEQ ID No.2. The present invention uses inactivated goat pox virus as an immunogen to immunize mice, and obtains the truncated protein rLP32Δ of the P32 protein with strong immunogenicity of LSDV through a prokaryotic system, and uses rLP32Δ to screen LSDV monoclonal antibody hybridoma cell lines and establish a subsequent ELISA detection method, thereby maintaining the natural conformation of the viral antigen to the greatest extent and greatly avoiding unnecessary biosafety risks.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a goat pox virus monoclonal antibody and application thereof. Background Art

[0002] Goat pox virus (GTPV) belongs to the Poxviridae family and the Capripoxvirus genus. It can infect sheep and goats and cause malignant pox diseases, including Kenyan sheep pox, goat pox, Indian sheep dermatitis, etc. Fine-wool sheep and lambs are most susceptible to the virus. Sick sheep show clinical manifestations such as fever, papules and herpes on the skin and mucous membranes of hairless or less hair, swollen lymph nodes, edema of the skin, emaciation, and a significant decrease in milk production, which seriously reduces the production performance of goats and the quality of wool and sheepskin products. The mortality rate of adult sheep with the disease can be as high as 42.06%, and the mortality rate of sick lambs can be as high as 100%. Once the disease occurs, it can cause huge economic losses.

[0003] The disease has occurred in many parts of the world, especially in North Africa, the Middle East and some countries in Asia, where it is more serious. The disease is also prevalent in neighboring countries of my country such as Nepal, Russia and India.

[0004] This disease is a Class A disease stipulated by OIE, and my country has classified it as a Class I animal epidemic disease. In addition, goat pox virus can also infect humans. A case of human infection with goat pox with specific etiological diagnosis basis occurred in Pengshui County, Chongqing City. Several cases of human infection with goat pox have also been reported in other regions. All cases have a history of contact with sick sheep and are contact infections. Therefore, the research on goat pox virus detection methods has important public health significance.

[0005] Although there is a commercial goat pox vaccine in my country, the lack of an effective GTPV antibody detection kit makes it difficult to screen goat pox antibody-negative animals during vaccine development, and the immune effect evaluation of target animals can only be done by virus neutralization test (VNT) involving live GTPV, which poses a major biosafety risk. Therefore, it is urgent to establish a rapid, sensitive, and specific GTPV antibody ELISA detection method.

[0006] The P32 protein of goat pox virus and its antigenicity have been disclosed in the prior art, but the obtained P32 protein is highly hydrophobic, which affects its biological application. The P32 protein obtained in the prior art mostly exists in the form of inclusion bodies, the amount of soluble protein is small, and the processing process of the expression product is complicated, and the expression amount is also low. Summary of the invention

[0007] The purpose of the present invention is to provide a recombinant GTPV P32 protein truncated protein rGP32Δ, and to provide a hybridoma cell line that secretes anti-GTPV, and to use the hybridoma cell line to prepare monoclonal antibodies, and further establish a blocking ELISA detection method for GTPV, thereby providing technical support for the development of GTPV vaccines and the development of alternative methods for efficacy testing.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows.

[0009] In a first aspect, the present invention provides an immunogenic protein rGP32Δ, wherein the coding sequence of the protein rGP32Δ is shown in positions 4 to 717 of SEQ ID No. 1;

[0010] In a specific embodiment, the coding sequence is optimized according to the preferred codons of Escherichia coli for the amino acid coding sequence of the P32 protein of GTPV at positions 1 to 238, and a 6×His tag is introduced at the C-terminus to synthesize the gene fragment GGP32Δ.

[0011] Furthermore, the amino acid sequence of the protein rGP32Δ is shown in positions 2 to 239 of SEQ ID No.2.

[0012] In a specific embodiment, the rGP32Δ protein is prepared by using the BL21 (DE3) cell strain of Escherichia coli, a host cell that recombinantly expresses rGP32Δ, as a production strain, which is the Escherichia coli BL322 strain.

[0013] Furthermore, the protein rGP32Δ is a soluble protein;

[0014] In a specific embodiment, the soluble protein rGP32Δ is obtained by fermentation culture, induced expression, bacterial cell disruption, and soluble antigen protein separation and purification of the production strain Escherichia coli BL / GP32 strain, and the preservation number of the Escherichia coli BL322 strain is CGMCC No.24529.

[0015] In a second aspect, the present invention provides a hybridoma cell line that secretes monoclonal antibodies against GTPV.

[0016] A hybridoma cell line secreting a monoclonal antibody against GTPV, wherein the hybridoma cell line is a GTPV hybridoma cell line p32-11;

[0017] Its accession number is CGMCC No.45132.

[0018] In a specific embodiment, the hybridoma cell line is prepared by the following method:

[0019] The inactivated goatpox virus S101 was used as an antigen to immunize animals, and the spleen cells of the immunized animals were fused with SP2 / 0 cells;

[0020] S102 fusion cells used the recombinant protein rGP32Δ to screen positive clones and subclones, and the hybridoma cell line that could stably secrete anti-GTPV monoclonal antibodies was the GTPV hybridoma cell p32-11.

[0021] In a third aspect, the present invention provides a monoclonal antibody against GTPV, wherein the monoclonal antibody is secreted by GTPV hybridoma cell p32-11;

[0022] The monoclonal antibody is monoclonal antibody p32-11.

[0023] In a specific embodiment, the monoclonal antibody p32-11 is obtained from the culture medium of GTPV hybridoma cell p32-11.

[0024] In another specific embodiment, the monoclonal antibody p32-11 is obtained by inoculating hybridoma cell line p32-11 into the peritoneal cavity of mice to produce ascites.

[0025] In a fourth aspect, the present invention provides a method for preparing an anti-GTPV polyclonal antibody.

[0026] A method for preparing anti-GTPV polyclonal antibodies comprises the following steps: immunizing sheep with a GTPV inactivated vaccine, and 14 days after the infection, separating the serum of the diseased sheep as the anti-GTPV polyclonal antibodies.

[0027] In a fifth aspect, the present invention provides a product for detecting capripox virus and uses thereof.

[0028] A product for detecting sheep pox virus, comprising monoclonal antibodies against GTPV.

[0029] A use of a monoclonal antibody against GTPV for preparing a medicament, a reagent, a test plate or a test kit;

[0030] The reagent, detection plate or kit is used to detect GTPV in a sample;

[0031] The agent is used for screening of antibody-negative animals for GTPV and / or testing of vaccine efficacy.

[0032] The preparation of monoclonal antibodies is the basis for establishing an excellent ELISA detection method, and the immunogen is the key to the preparation of monoclonal antibodies. To this end, the present invention uses inactivated GTPV as an immunogen to immunize mice, and obtains a truncated protein (rGP32Δ) of the P32 protein with strong immunogenicity of GTPV through a prokaryotic system, and uses rGP32Δ to screen GTPV monoclonal antibody hybridoma cell lines and establish subsequent ELISA detection methods, thereby maintaining the natural conformation of the viral antigen to the greatest extent while greatly avoiding unnecessary biosafety risks.

[0033] At the same time, the present invention uses the monoclonal antibodies obtained by screening to establish a blocking ELISA detection method for GTPV antibodies, thereby providing technical support for the research of GTPV-related vaccines and the development of alternative methods for efficacy testing.

[0034] The present invention is the first to obtain the GTPV truncated recombinant P32 protein rGP32Δ expressed in a soluble form through an E. coli expression system, and for the first time uses the protein as a coating antigen and inactivated goat pox virus as an immune antigen to screen anti-monoclonal antibody hybridoma cell lines and establish GTPV antibody blocking ELISA. The present invention has the following advantages:

[0035] (1) For the first time, through codon optimization and artificial synthesis technology, the soluble expression of the recombinant protein rGP32Δ of GTPV was achieved through the Escherichia coli expression system, thus avoiding the complexity of inclusion body protein purification.

[0036] (2) For the first time, an exogenous expression system was used to obtain the recombinant protein of GTPV and inactivated goat poxvirus to prepare monoclonal antibodies, which can reduce the biosafety risks of GTPV.

[0037] (3) For the first time, rGP32Δ with a purity of more than 90% was used as the coating antigen to establish GTPV antibody blocking ELISA, which not only ensured the purity of the coating antigen but also solved the safety risks of GTPV.

[0038] The present invention is the first to establish an antibody blocking ELISA detection method for GTPV using anti-GTPV monoclonal antibodies and rGP32Δ. This method also has the characteristics of simple sample operation, low cost, rapid reaction, and strong specificity, thereby providing a basis for the screening of antibody-negative animals for GTPV and the research on alternative methods for related vaccine efficacy testing. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The results show the identification of soluble expression of rGP32Δ.

[0040] Figure 2 The figure shows the SDS-PAGE identification result of rGP32Δ purification.

[0041] Figure 3 This is the result of identifying the purification effect of monoclonal antibody p32-11.

[0042] Figure 1 In the table, M is a protein marker; PC1 is BSA (1 μg); PC2 is BSA (2 μg); 1 is uninduced cell lysate; 2 is cell lysate induced at 15°C and 16 h; 3 is cell lysate induced at 37°C and 4 h; 4 is supernatant of uninduced cell lysis; 5 is supernatant of cell lysis induced at 15°C and 16 h; 6 is supernatant of cell lysis induced at 37°C and 4 h; 7 is precipitate of uninduced cell lysis; 8 is precipitate of cell lysis induced at 15°C and 16 h; 9 is precipitate of cell lysis induced at 37°C and 4 h.

[0043] Figure 2 In the figure, M is Protein marker; BSA is 1 μg BSA; P32 is purified rGP32Δ.

[0044] Figure 3 In the figure, M is the protein marker; 1 is the purified p32-11. DETAILED DESCRIPTION

[0045] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail in the following examples. The following examples are only used to illustrate the invention but are not used to limit the scope of the present invention.

[0046] Example 1

[0047] Preparation of rGP32Δ

[0048] 1. Construction of rGP32Δ expression vector

[0049] (1) Gene synthesis

[0050] The 1st to 238th amino acid coding sequence of the P32 protein of GTPV (GenBank: MG458384.1) was optimized according to the preferred codons of Escherichia coli, and a 6×His tag was introduced at the C-terminus. The gene fragment GGP32Δ was artificially synthesized by chemical synthesis, which contained a total of 744 nucleotides. The specific nucleic acid sequence is shown in SEQ ID No.1; the specific amino acid sequence is shown in SEQ ID No.2.

[0051] (2) Construction of fusion expression vector

[0052] The synthetic GGP32Δ gene was used as a template and primer pair 1F / 1R was used for PCR amplification.

[0053] The sequence of the upstream primer 1F is: 5'-cggccatatggcagatattcc-3'; the restriction endonuclease Nde I site and protective bases are introduced into the 5' end.

[0054] The sequence of the downstream primer 1R is: 5'-ccgcaagcttttagtggtgatg-3'; a restriction endonuclease Hind III site and protective bases are introduced into the 5' end thereof.

[0055] The PCR system is: Buffer(Mg 2+ plus) 10 μL, dNTPs 4 μL, upstream and downstream primers 1 μL each, 1 μL HS polymerase, 2 μL DNA template, add ddH2O to 50 μL system.

[0056] The PCR reaction conditions were as follows: pre-denaturation at 98°C for 1 min; denaturation at 98°C for 10 s, annealing at 56°C for 30 s, extension at 72°C for 1 min, for a total of 33 cycles; and final loop extension at 72°C for 10 min.

[0057] The amplified target DNA band was recovered and digested with Nde I / Hind III double enzymes, and ligated with the pET30a vector digested with the same enzymes to obtain the GGP32Δ gene-inserted positive clone pET30a-GGP32Δ. The obtained prokaryotic expression plasmid pET30a-GGP32Δ was transformed into DH5α competent cells, and a single clone was picked out and placed in LB liquid culture medium containing kanamycin, cultured at 37°C with shaking overnight, and the plasmid was extracted for later use.

[0058] 2. Expression and purification of rGP32Δ

[0059] (1) Construction of genetically engineered strains carrying the recombinant GGP32Δ gene

[0060] The extracted plasmid was transformed into Escherichia coli BL21 (DE3) competent cells, and a single clone was picked out and placed in LB liquid medium containing kanamycin. It was cultured at 37°C overnight with shaking. After PCR identification, it was named Escherichia coli BL322 strain after containing the target DNA fragment. An equal volume of 50% glycerol LB was added and frozen at -70°C.

[0061] (2) Expression and purification of rGP32Δ

[0062] The recombinant Escherichia coli (E. coli) BL322 strain was inoculated into 1 L LB liquid medium containing kanamycin for fermentation and cultured at 37°C with shaking until OD 600When the pH value was 0.6-0.8, IPTG solution with a final concentration of 0.5 mM was added to induce culture for 4 h.

[0063] After the bacterial culture was completed, the cells were collected by centrifugation and resuspended in a ratio of 10 mL of lysis solution [0.02 mol / L Tris buffer (pH 7.2), 0.3 mol / L NaCl] per gram of cell weight. The cells were ultrasonically disrupted in an ice-water bath for 30 min. The disruption conditions were: working for 9 s, resting for 9 s, and the ultrasonic power was 400 W. The soluble expression identification results were as follows: Figure 1 shown.

[0064] The disrupted bacterial solution was centrifuged at 4°C and 12,000 r / min for 10 min, and the supernatant was collected. The soluble target protein in the bacterial lysis supernatant was purified according to the instruction manual of the Ni-IDA affinity chromatography medium kit (Nanjing GenScript Co., Ltd.) and filtered through a 0.22 μm pore size filter membrane to obtain the initially purified target protein. The SDS-PAGE identification results of the purified rGP32Δ are shown in Figure 2. Figure 2 shown.

[0065] Example 2

[0066] Screening of hybridoma cell lines secreting monoclonal antibodies against GTPV P32 protein and preparation of monoclonal antibody ascites

[0067] 1. Immunization of BALB / c mice and determination of antibody titers

[0068] Three BALB / c mice aged 6 to 8 weeks were immunized with inactivated goat pox virus as the immunization antigen for a total of four immunizations, with an interval of 2 weeks between each immunization.

[0069] For the first immunization, add an equal volume of Freund's complete adjuvant to the protein, emulsify it, and immunize mice through multiple subcutaneous injections at the back of the neck, 50μg / mouse; for subsequent immunizations, the adjuvant is replaced with Freund's incomplete adjuvant, and the rest is the same as the first immunization; 7 to 10 days after the third immunization, a small amount of blood is collected from the tail, and the serum titer is determined by indirect ELISA by coating the purified rGP32Δ with 2μg / mL on an enzyme-labeled plate. Mice with a titer higher than 1:4000 are selected for booster immunization three days before fusion, and the protein is directly injected intraperitoneally at a dose of 50μg / mouse. 3 to 5 days after the last immunization, the spleen cells of the mouse with the highest titer are taken for cell fusion.

[0070] 2. Cell fusion and screening of hybridoma cell lines

[0071] Myeloma cells SP2 / 0 with good growth status were chemically fused with the spleen cells of mice with the highest titer detected by ELISA using PEG1450. Positive hybridoma cells were screened by indirect ELISA method with rGP32Δ as coating antigen. After 3 to 5 subclonings by limiting dilution method, a hybridoma cell line p32-11 secreting P32 protein against GTPV was obtained. According to the instructions of IsoQuickTMStrips and Kits for Mouse Monoclonal Isotyping kit, the monoclonal antibody subtype secreted by this hybridoma cell line was G2a.

[0072] 3. Preparation of Ascites with Monoclonal Antibodies against P32 Protein of GTPV

[0073] Select healthy multiparous BALB / c mice aged 6 to 8 months, sensitize them with Freund's incomplete adjuvant intraperitoneally, 0.5 mL / mouse, and inject hybridoma cells 7 days later. Collect the above three hybridoma cells in logarithmic growth phase and SP2 / 0 cells, centrifuge at 800r / min for 10min, wash the cells once with DMEM culture medium, resuspend them, adjust the cell density to 106 / mL, and inject 0.5mL into each mouse intraperitoneally. Gently rub the mouse abdomen with alcohol cotton to evenly disperse the cells in the abdominal cavity; after 7 to 14 days, when the mouse abdomen is obviously swollen, use the needle of a 20ml syringe to sterilely pierce the swollen part of the mouse abdomen, gently rub and press, so that the ascites flows out or drips out; collect the ascites in a 15ml centrifuge tube, centrifuge at 3000r / min for 10min, mark as p32-11 and ascites control (S) of myeloma cells SP2 / 0, and store them at -20℃ for later use after aliquoting.

[0074] Example 3

[0075] Purification and detection of monoclonal ascites

[0076] Protein A (GE Healthcare 17-5079-01) affinity column purification method was used for purification, and the purification steps were as follows:

[0077] Sample pretreatment: dilute the ascites with coupling buffer (20 mM sodium phosphate buffer, pH 7.0) at a ratio of 1:3, centrifuge at 12,000 rpm, 4°C for 10 min, and filter with a 0.22 μm filter membrane to remove fat, cell debris and small particles.

[0078] Equilibration: Equilibrate the column with 5 to 10 column volumes of coupling buffer, maintaining a flow rate of 2 s / drop.

[0079] Loading: Use a syringe to inject the sample into the upper interface of the column, collect the effluent in a 50ml centrifuge tube, and maintain a flow rate of 4s / drop.

[0080] Washing: Pass 5 column volumes of coupling buffer through the column, maintaining a flow rate of 2s / drop.

[0081] Elution: Elute the antibody with 5 column volumes of elution buffer (0.1 M sodium citrate buffer, pH 9.0), collect in the above EP tube, and maintain the flow rate at 4 s / drop.

[0082] Sample detection: The purified monoclonal antibody was identified by SDS-PAGE, and a high-purity monoclonal antibody was obtained by purification using a Protein A affinity column; the BCA method was used to determine the concentration of the monoclonal antibody, and its concentration could reach 2.62 mg / mL.

[0083] The results of purification of monoclonal antibody p32-11 are as follows Figure 3 shown.

[0084] Example 4

[0085] Establishment of a blocking ELISA assay for goat poxvirus (GTPV) antibodies based on monoclonal antibody p32-11

[0086] 1. Preparation of anti-GTPV polyclonal antibodies:

[0087] Sheep were selected as immunized animals and immunized three times with 2 doses of GTPV inactivated vaccine, with an interval of 14 days between each immunization. 14 days after the third immunization, sheep serum was collected for standby use.

[0088] 2. Determination of the blocking ELISA test conditions for GTPV antibodies

[0089] (1) Optimal working concentrations of goat anti-GTPV polyclonal and monoclonal antibodies

[0090] The purified rGP32Δ was diluted to 2 μg / ml with PBS, 100 μL / well, blocked overnight at 4°C, washed three times with PBST, and PBST solution containing 5% skim milk powder was added as blocking solution, 200 μL / well, blocked overnight at 4°C;

[0091] The plate was washed three times with PBST solution, and the 96-well ELISA plate was patted dry and stored at -20°C for future use.

[0092] Take out the coated 96-well ELISA plate from the -20℃ refrigerator, place it at room temperature for 30 minutes, add the obtained sheep anti-GTPV polyclonal antibody, use PBS as the diluent, the dilution is 1:20, 1:40 and 1:80, 100 μL / well, add the negative serum of the corresponding dilution at the same time, and incubate at 37℃ for 1 hour.

[0093] Wash three times with PBST solution, add p32-11, use PBS as the diluent, dilute the concentration serially from 2000 times to 16,000 times, 100 μL / well, and incubate at 37°C for 30 minutes.

[0094] The cells were washed three times with PBST solution, and 50 μL / well of soluble TMB substrate colorimetric solution was added. The cells were reacted for 15 min at room temperature in the dark. The reaction was terminated with 2 M H2SO4 solution, and the absorbance was read at 450 nm.

[0095] The OD value of the negative control well is selected to be close to 1.0, and the dilution corresponding to the positive serum blocking rate ≥50% is the optimal working concentration.

[0096] The working dilution of sheep anti-GTPV polyclonal antibody was finally determined to be 1:40, and the working concentration of p32-11 was 1:16,000.

[0097] (2) Determination of the criteria for judging the results

[0098] The established antibody blocking ELISA was used to detect 63 sheep serum samples, and positive and negative controls were set up.

[0099] ˉ

[0100] Determination of OD 450 , the calculated average value (x) = 5.619% and the standard deviation (S) = 6.108%.

[0101] ˉˉ

[0102] When PI≥x+3s (23.9%), the serum is judged as positive; when PI≤x+2s (17.8%), it is negative. For those between the two, it is judged as suspicious and needs to be retested. If it is still suspicious, it is judged as positive.

[0103] (3) Specific detection of GTPV antibody blocking ELISA method

[0104] The positive serum of sheep Escherichia coli disease antibody, sheep oral sore virus positive serum, sheep putrefactive Clostridium toxin, A and D type Clostridium perfringens toxin antibody positive serum was diluted 1:40 and then tested by ELISA. The results showed that the above sera were all negative, indicating no cross reaction, indicating that the method has good specificity.

[0105] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various changes can be made to the technical scheme of the present invention. These simple variations all belong to the protection scope of the present invention.

[0106] It should also be noted that the various specific technical features and steps described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0107] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention. Sequence Listing <110> China Veterinary Drug Administration <120> A goat pox virus monoclonal antibody and its application <141> 2022-04-22 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 744 <212> DNA <213> Artificial Sequence <400> 1 catatggctg acatcccgct gtatgtgatc ccgattgttg gtcgtgaaat ctctgacgtg 60 gtcccggaac tgaaatctgg taatgatatt ttttataaaa aagtcgatac cgtgaaagac 120 ttcaaaaact ctgatgtcaa atttttcctg aaagataaaa aagacatcag cctgtcttac 180 aaattcctga tctgggaaaa ggtagaaaaa tcaggaggtg ttgaaaattt tacagaatat 240 ttttctggat tatgtaatgc tctttgtaca aaagaggtaa aaagttctat tgcaaaacac 300 tttagtttat ggaaatcgta tgccgatgcg gatataaaaa attctgagaa taagtttatt 360 gttgttatag aagatgata cacattaaaa gatttaata cattaata cattattatt 420 gaatgcaag aaaaaaat agacatttc caattacgtg aaacttttca taatagtaat 480 tctagaatat tgttcaatca agaaataat aattttatgt attcgtacac agggggatat 540 gattttacct tatctgcata cgtaattaga ttatcgtctg ccataaaaat aaaacgaa 600 attaaaaa aaaggtat ttctaccagt ttgagttttg aaatgtataa gttggaaaaa 660 gattaaac tcaatagaca agttttaat gactcatcta agtatatact tcacaatcat 720 catcaccatc accactaaaa gctt 744 <210> 2 <211> 245 <212> PRT <213> recombinant p32 of lumpy skin disease virus <400> 2 His Met Ala Asp Ile Pro Leu Tyr Val Ile Pro Ile Val Gly Arg Glu 1 5 10 15 Asp Val Val Pro Glu Leu Lys Ser Gly Asn Asp Ile Phe Tyr 20 25 30 Lys Lys Val Asp Thr Val Lys Asp Phe Lys Asn Ser Asp Val Lys Phe 35 40 45 Phe Leu Lys Asp Lys Lys Asp Ile Ser Leu Ser Tyr Lys Phe Leu Ile 50 55 60 Trp Glu Lys Val Glu Lys Ser Gly Gly Val Glu Asn Phe Thr Glu Tyr 65 70 75 80 Phe Ser Gly Leu Cys Asn Ala Leu Cys Thr Lys Glu Val Lys Ser Ser 85 90 95 Ile Ala Lys His Phe Ser Leu Trp Lys Ser Tyr Ala Asp Ala Asp Ile 100 105 110 Lys Asn Ser Glu Asn Lys Phe Ile Val Val Ile Glu Asp Asp Asn Thr 115 120 125 Leu Lys Asp Leu Ile Thr Ile Tyr Asn Ile Ile Ile Glu Met Gln Glu 130 135 140 Lys Asn Ile Asp Ile Phe Gln Leu Arg Glu Thr Phe His Asn Ser Asn 145 150 155 160 Ser Arg Ile Leu Phe Asn Gln Glu Asn Asn Asn Phe Met Tyr Ser Tyr 165 170 175 Thr Gly Gly Tyr Asp Phe Thr Leu Ser Ala Tyr Val Ile Arg Leu Ser 180 185 190 Ser Ala Ile Lys Ile Ile Asn Glu Ile Ile Lys Asn Lys Gly Ile Ser 195 200 205 Thr Ser Leu Ser Phe Glu Met Tyr Lys Leu Glu Lys Glu Leu Lys Leu 210 215 220 Asn Arg Gln Val Leu Asn Asp Ser Ser Lys Tyr Ile Leu His Asn His 225 230 235 240 His His His His His 245

Claims

1. A hybridoma cell line secreting a monoclonal antibody against GTPV, characterized in that: The hybridoma cell line is GTPV hybridoma cell p32-11; its preservation number is CGMCC No.45132; the monoclonal antibody produced by the hybridoma cell line can bind to the rGP32Δ protein; the rGP32Δ protein is shown in positions 4 to 717 of SEQ ID No.1, which is obtained by optimizing the amino acid coding sequence of positions 1 to 238 of the P32 protein of GTPV according to the preferred codons of Escherichia coli, and introducing a 6×His tag at the C-terminus to synthesize the gene fragment GGP32Δ.

2. A kit comprising the monoclonal antibody secreted by the hybridoma cell line according to claim 1.

Citation Information

Patent Citations

  • Colloidal gold test strip for detecting goatpox virus and preparation method thereof

    CN104407130A

  • An enzyme-linked immunosorbent assay kit for detecting a sheep pox virus antibody and applications thereof

    CN107894506A

  • Recombinant sheep pox virus fusion protein and application thereof

    CN108101995A

  • Preparation method for p32 soluble protein of goat poxvirus

    CN109957575A